ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

recombinant FVIIa

Also written as “activated recombinant human factor VII”, “eptacog alfa (activated)” and “Coagulation Factor VIIa (Recombinant)”.

Its studies are mostly in Hemophilia A · Cerebral Hemorrhage · Wounds and Injuries · Fibrosis · Postpartum Hemorrhage, led by 4 companies.

Drug pageRecombinant FVIIa: every studyAll 58 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Dec 11, 200741 company-led studies, 1 open or runningNext primary completion: Aug 26, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordiskits history only361 open or runningphase 4since Dec 11, 2007Jan 19, 2005Aug 26, 2027phase 4 · NCT07157423
Laboratoire français de Fractionnement et de Biotechnologiesits history only20 open or runningphase 3since Sep 9, 2015Sep 9, 2015none ahead
rEVO Biologicsits history only20 open or runningphase 3since Dec 18, 2013Oct 15, 2012none ahead
AryoGen Pharmed10 open or runningphase 3since Mar 4, 2017Mar 4, 2017none ahead

Also a collaborator on its studies: LFB USA.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AryoGen Pharmed only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 4, 2017First study: phase 3 study in Factor VII DeficiencyFirst studyNCT03079063 · 24 enrolled · Iran, Islamic Republic of

TargetBeta

F7 →read by rule
“A recombinant form of the vitamin K-dependent glycoprotein and coagulation factor VIIa (FVIIa), that can be used for the treatment of bleeding episodes and perioperative management in patients with hemophilia, congenital Factor VII (FVII) deficiency, and Glanzmann's thrombasthenia”NCIt, by rule

Studies

The one study AryoGen Pharmed leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03079063Factor VII Deficiency · Iran, Islamic Republic of3CompletedNov 30, 202024

How it is read

Names in the registry

  • “activated recombinant human factor VII”, 32 entries
  • “eptacog alfa (activated)”, 12 entries
  • “Coagulation Factor VIIa (Recombinant)”, 3 entries
  • “Eptacog alfa (NovoSeven)”, 1 entry
  • “Eptacog alfa, biosimilar”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.